Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
(HealthDay News) – The LAP-BAND adjustable gastric banding system (LAGB) is safe and effective for obese individuals with a body mass index (BMI) of 30–39.9kg/m², according to a study published online May 2 in Obesity.
To examine the safety and effectiveness of the LAGB system for patients with a BMI of 30–39.9kg/m², Robert Michaelson, from Northwest Weight Loss Surgery in Everett, Wash., and colleagues recruited 149 subjects (90.6% female; mean BMI, 35.3kg/m²), who had failed prior weight loss attempts, from seven surgical centers.
The researchers found that, at one year, 84.6% of subjects achieved ≥30% excess weight loss (EWL), with a mean EWL of 65%. In addition, 66.4% of the participants were no longer obese (BMI, <30kg/m²). For 64.4% of those with dyslipidemia, 59.6% with hypertension, and 85.7% with diabetes, improvements were seen in baseline comorbidities at one year. There was also significant improvement in quality-of-life (IWQOL-Lite), with the results from year-one maintained or improved at two years. Each additional 10% weight loss at year-two correlated with a 7.1% increase in IWQOL-Lite, and with decreases of 13.7mg/dL in triglycerides; 3.5mg/dL in fasting glucose; and 3.3mmHg in systolic blood pressure. Adverse events were generally mild to moderate and resolved within one month.
“LAGB is a safe and effective treatment option for obese people with a BMI of 30–39.9, with weight loss and comorbidity improvement through ≥two years,” the authors write.
Allergan, the maker of the Lap-Band, designed and funded the study and performed statistical analysis of the data. Several authors disclosed financial ties to Allergan.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
